Development and validation of prognostic models using novel inflammatory markers for drug reactions with eosinophilia and systemic symptoms: An international multicenter cohort study - 18/09/25

Abstract |
Background |
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a life-threatening disease that has received little attention focusing on its prognostic markers.
Objective |
We evaluated the association between novel inflammatory markers and in-hospital mortality. We also proposed and validated a risk stratification model to aid early intervention.
Methods |
This international multicenter, retrospective cohort study included 169 patients diagnosed with DRESS from Taiwan, Singapore, and Japan, collecting demographics and laboratory markers within 3 days of diagnosing DRESS. Inflammatory markers were calculated, and statistical analyses, including logistic regression and receiver operating characteristic curve analysis. Predictive models were developed with internal validation using leave-one-out cross-validation.
Results |
Lower hemoglobin-to-red blood cell distribution width ratio, higher platelet-to-lymphocyte ratio, and lower monocyte count are identified as significant predictors of mortality in a multivariate analysis. A predictive model for DRESS-related mortality, incorporating the significant inflammatory markers and underlying disease (malignancy, autoimmune disease, and cardiovascular disease), demonstrated good discrimination ability and acceptable accuracy.
Limitation |
The retrospective design, along with factors like interhospital transfers, and underlying malignancies are limitations.
Conclusion |
The presence of these novel inflammatory markers and the development of risk stratification model may be of value to stratification of the severity of DRESS.
Le texte complet de cet article est disponible en PDF.Key words : drug reaction with eosinophilia and systemic symptom, prognostic models, novel inflammatory markers, risk stratification, severe cutaneous adverse reaction
Abbreviation used : AUC, CI, COPD, DRESS, HRR, LMR, NLR, NTUH-SCU, PLR, RBC, RDW, ROC, SCAR, SCORTEN, SD, TARC, Treg
Plan
| Funding sources: None. |
|
| Patient consent: Not applicable. |
|
| IRB approval status: Institutional research ethics committee of National Taiwan University (#202202067RIND). |
Vol 93 - N° 4
P. 1027-1034 - octobre 2025 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
